Research programme: antibacterials - Morphochem

Drug Profile

Research programme: antibacterials - Morphochem

Alternative Names: Bacterial topoisomerase I inhibitors - Morphochem; Enzyme inhibitors - Morphochem; MCB 1033; MCB 116; MCB-4657; MCB-4658; MCTI programme - Morphochem; Topoisomerase inhibitors - Morphochem; Topoisomerase IV inhibitors - Biovertis

Latest Information Update: 12 Jun 2007

Price : $50

At a glance

  • Originator Morphochem AG
  • Class Oxazolidinones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Bacterial infections

Most Recent Events

  • 15 Dec 2006 Suspended - Preclinical for Bacterial infections in Switzerland (unspecified route)
  • 15 Dec 2006 Suspended - Preclinical for Bacterial infections in USA (unspecified route)
  • 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the Bacterial Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top